Key Takeaways
- Record profit, powered by one molecule: PAT hit a quarterly high of ₹99 crore, driven by a 352% YoY surge in pharmaceutical intermediates revenue to ₹266.3 crore as new capacity for a cardiovascular intermediate came fully online.
- Contrast media degrew, but the story is about the ramp: Segment turnover fell ~17% to ₹302.8 crore on customer offtake issues, yet validation batches for a new NCE molecule shipped and two new launches are imminent, setting up a step-increase conviction for the medium term.
- Mix shift compressed gross margins: Gross margin dipped 2% to 55% for 9M as the higher-growth, lower-margin pharmaceutical intermediate mix increased; management expects EBITDA margin to sustain at 35%-37% if Q3 turnover levels hold.
- R&D and capacity bets are scaling up: A ₹40 crore R&D investment targets advanced intermediates, contrast media expansion, and peptide/GLP-1 capabilities, while Unit 3 at Mahad is being redesigned for continuous processing ahead of an H2 FY26 go-live.
- What to watch next quarter: Whether the two new contrast media launches translate into higher customer offtake, the pace of capacity utilization optimization for contrast media, and any visibility on the peptide intermediate pipeline.
The Cardiovascular Intermediate Surge
- One product, step-change growth: The cardiovascular intermediate drove pharmaceutical intermediates turnover up 352% YoY, with U.S. retail prescription equivalents growing ~15% QoQ and over 50% annually. European growth, especially in Germany, is expected to be even stronger.
- Capacity built for the upside: The Unit 2 Phase 1 plant (120 KL) is running optimally, with design capacity intentionally higher than current output because of a positive product outlook tied to label expansions, Phase 3 data, and a settlement. Management stated that even doubling capacity is feasible via debottlenecking.
- Volume sustainability looks solid: Based on the current order book and customer forecast, the short-to-medium-term outlook is encouraging, and management believes similar growth can be sustained in coming years.
- The molecule is on a blockbuster path: The opportunity outside the U.S. is even larger if statins are the benchmark; Europe is bigger than the U.S., Japan will be a very credible market, and Latin American growth is described as phenomenal.
VK Singh: "Our capacities are often co-engineered and build-to-suit to support our go-to-market that is largely innovator-oriented."
Contrast Media: A Tale of Two Halves
- Current product degrew on supply issues: Segment turnover fell ~17% to ₹302.8 crore due to customer offtake issues beyond the company's control in prior quarters. Supply issues have been partially resolved, and the flagship product's market share remains stable and robust.
- Growth should track the market: Management stated the existing flagship contrast media product's growth should be benchmarked to the broader contrast agents market growth of 7%-8%.
- New launches are the catalyst: Two new contrast media launches are expected; once they happen, higher growth will be seen. One new product will be launched shortly, with customer response determining the pace of offtake.
- Step-increase conviction is high: Management expressed very high conviction that the contrast media business can see a step increase in revenue over a 2-3 year period if they forward integrate on any of those products.
- Backward integration closes the last gap: The company is majorly backward integrated in contrast media, giving cost and quality leadership. The one missing link, a particular imported raw material, will be manufactured at one of their sites in the short to medium term.
- NCE molecule production started: Commercial production for an NCE molecule began from a new block this quarter, with validation batches for the contrast media intermediate successfully completed and first quantities shipped to the customer.
Shiven Arora: "Yes. There would be a very high conviction around that, very, very high, yes."
Capacity Build-Out: Unit 2 Live, Unit 3 Next
- Unit 2 Phase 1 (120 KL) is fully operational and producing the cardiovascular intermediate optimally.
- Unit 2 Phase 2 (37 KL) has gone live; validation batches for a contrast media intermediate were successfully completed and first quantities shipped.
- Unit 3 at Mahad is progressing: common utilities are nearing completion, and the process has been redesigned for continuous processing based on good data and proof of concept. Additional products have been added to that site per customer requirements.
- Contrast media capacity optimization is expected by H1 2026, with Unit 3 go-live targeted for H2 FY26. A new advanced intermediate is expected to go live in Q1 FY26.
VK Singh: "This change, when implemented, shall deliver higher and more consistent quality, be safer and have a lower physical and carbon footprint."
R&D and the Peptide Bet
- ₹40 crore R&D investment has been decided, focusing on advanced intermediates, expanding the contrast media portfolio, and enhancing CDMO capabilities. A second very significant R&D expansion is underway, with R&D hardware and the talent pool doubled in the past 18 months.
- Peptide intermediates are a new chemistry platform: The company is augmenting R&D capability to work on advanced intermediates for peptide products, specifically amino acid derivatives. Roughly one-quarter of the new R&D infrastructure will be dedicated to the peptide/GLP-1 segment.
- No fermentation, high-value niche: The company is not setting up fermentation capacity; it will handle stages after the amino acid stage. The peptide intermediate business will require specialized equipment and is a relatively smaller-volume, high-value type of business.
- Opportunities span the development curve: The company is working on products already commercial and on the market (still under patent), some in Phase 3, and some in Phase 1 and Phase 2. They will commercialize in a staggered way.
- No timeline given: Management declined to provide any timeline or guidance on when the first peptide intermediate businesses will materialize.
Margins, Mix, and the Guidance That Wasn't
- Gross margin dipped on mix: Gross margin for 9M was 55%, down 2%, as the share of pharmaceutical intermediates increased. Raw material prices are stable with no significant variance expected.
- Operational leverage kicked in: The step-up growth in Q3 pushed EBITDA margin to 39% for the quarter versus 34.5% for 9M. Management believes sustaining similar turnover levels can improve EBITDA margin annually.
- The 35%-37% EBITDA signal, not a guide: Management stated that a sustained level of activities based on Q3 should yield EBITDA in excess of 35%-37%, but explicitly declined to upgrade formal guidance, citing the need to assess how the new R&D investment will impact FY26 operating costs.
- Cost structure is lean: Salaries as a percentage of sales were lower in Q3; absolute numbers were marginally up due to team build-up for expansions. No significant one-off impact on freight or power costs this quarter.
- Working capital to optimize: An increase of ₹120 crore in working capital will be optimized over a period of time.
Ganesh Karuppannan: "We don't want to give any guidance at this stage because we also have the new R&D coming in, and we need to actually like make an assessment how the operating costs are going to be for FY 26."
The Moat: No Generics, Sticky Customers
- Not in the generic space: Management emphasized that the entire business is innovator-oriented. In contrast media, there is no generic competition. For pharmaceutical intermediates, there is no indication of any recalibration on realizations in the near future. Price erosion is not a threat at this point.
- Contracts protect margins: The company is covered by FCA (Force Majeure/price adjustment clauses); margins are described as sustainable.
- Saccharin is a 150-year annuity: The sweetener segment is in a niche FMCG/pharma space with high business stickiness. The company has not lost a single saccharin customer in the last 5-6 years. Competition from China exists but operates in a different segment.
VK Singh: "Saccharin has been on the market for 150 years. So, this was invented 150 years back. I think it's the most stable product, both in chemistry and demand."
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| Contrast media capacity optimization | Optimize capacity utilizations for contrast media | H1 2026 |
| Unit 3 go-live | Unit 3 at Mahad to go live | H2 FY26 |
| New advanced intermediate launch | New advanced intermediate to go live | Q1 FY26 |
| EBITDA margin signal | Sustained Q3-level activity should yield EBITDA in excess of 35%-37% | Conditional on turnover levels holding |
| R&D investment | ₹40 crore investment in R&D infrastructure and capabilities | FY26 |
| Backward integration | Manufacture the one missing imported raw material for contrast media at own site | Short to medium term |
Key Metrics
| Metric | Q3 FY25 |
|---|---|
| Revenue | ₹318.4 cr, +53% QoQ and +91% YoY |
| EBITDA | ₹124 cr, +79% QoQ and +127% YoY |
| PAT | ₹99 cr, +70% QoQ and +208% YoY, highest ever quarterly profit |
| EBITDA margin | 39% of sales; 9M FY25 at 34.5% |
| PAT margin | 28.3% for 9M FY25 |
| 9M FY25 revenue | ₹689.5 cr, +31% YoY |
| 9M FY25 pharmaceutical intermediates turnover | ₹266.3 cr, +352% YoY |
| 9M FY25 contrast media segment turnover | ₹302.8 cr, degrowth of ~17% |
| Saccharin category 9M FY25 turnover | ₹103.8 cr, +10% YoY |
| Gross margin | 55% for 9M FY25, down 2 ppt due to product mix change |
| Total cash, investments and bank balance | ₹331.3 cr, down ₹21 cr vs September |
| Working capital increase | ₹120 cr in 9M FY25, predominantly for pharma intermediate inventory |
| R&D investment planned | ₹40 cr capex in FY26, with operating expense expected at ₹10–12 cr vs current ₹5–6 cr |
| Capacity addition (Unit 2) | 120 KL Phase 1 operational; 37 KL Phase 2 live with validation batches shipped |
| Cardiovascular product US prescription growth | ~15% QoQ retail prescription equivalent |